Description: Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, “ARCUS.” Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
Home Page: www.precisionbiosciences.com
DTIL Technical Analysis
302 East Pettigrew Street
Durham,
NC
27701
United States
Phone:
919 314 5512
Officers
| Name | Title |
|---|---|
| Mr. Michael Amoroso | Pres, CEO & Director |
| Dr. Derek Jantz Ph.D. | Co-Founder, Chief Scientific Officer & Strategy |
| Mr. John Alexander Kelly | Chief Financial Officer |
| Dr. Jefferson J. Smith Ph.D. | Co-Founder & Chief Research Officer |
| Mr. Shane Barton | VP, Corp. Controller & Principal Accounting Officer |
| Mei Burris | Director of Investor Relations & Fin. |
| Mr. Dario Scimeca | Gen. Counsel & Sec. |
| Mr. Bruce Stevens | VP of Quality & Compliance |
| Ms. Heather King | Director of Marketing Communications & PR |
| Maurissa Messier | Sr. Director of Corp. Communications |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6174 |
| Price-to-Sales TTM: | 6.3895 |
| IPO Date: | 2019-03-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 194 |